The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos
- PMID: 2112493
- DOI: 10.1016/s0015-0282(16)53591-2
The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos
Abstract
Severe ovarian hyperstimulation syndrome complicates up to 6% of IVF treatment cycles. We have utilized our pre-embryo cryopreservation program to manage incipient ovarian hyperstimulation syndrome in an alternative way. Four women, who were at risk of developing ovarian hyperstimulation syndrome, underwent oocyte retrieval, but not embryo replacement. Instead, resulting pre-embryos were cryopreserved for future transfer. The four patients have since become pregnant. Three conceived after thawed embryo replacement cycles, and the fourth conceived spontaneously 1 month after the stimulation cycle. This approach offers maximum flexibility in the management of ovarian hyperstimulation syndrome.
Similar articles
-
Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome.J Assist Reprod Genet. 1996 Apr;13(4):293-7. doi: 10.1007/BF02070141. J Assist Reprod Genet. 1996. PMID: 8777342
-
Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome.Reprod Biol. 2018 Mar;18(1):46-52. doi: 10.1016/j.repbio.2017.12.004. Epub 2017 Dec 24. Reprod Biol. 2018. PMID: 29279182
-
Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome.Hum Reprod. 1992 Aug;7(7):962-6. doi: 10.1093/oxfordjournals.humrep.a137779. Hum Reprod. 1992. PMID: 1430136
-
The prevention of ovarian hyperstimulation syndrome.J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5. J Obstet Gynaecol Can. 2014. PMID: 25574681 Review. English, French.
-
Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature.Gynecol Endocrinol. 2012 Jul;28(7):545-8. doi: 10.3109/09513590.2011.650745. Epub 2012 Mar 23. Gynecol Endocrinol. 2012. PMID: 22439899 Review.
Cited by
-
Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome.J Assist Reprod Genet. 1996 Apr;13(4):293-7. doi: 10.1007/BF02070141. J Assist Reprod Genet. 1996. PMID: 8777342
-
Safety of drugs used in assisted reproduction techniques.Drug Saf. 2005;28(6):513-28. doi: 10.2165/00002018-200528060-00004. Drug Saf. 2005. PMID: 15924504 Review.
-
Clinical outcomes of frozen embryo transfer cycles after freeze-all policy to prevent ovarian hyperstimulation syndrome.Obstet Gynecol Sci. 2018 Jul;61(4):497-504. doi: 10.5468/ogs.2018.61.4.497. Epub 2018 Jun 20. Obstet Gynecol Sci. 2018. PMID: 30018904 Free PMC article.
-
Prevention of ovarian hyperstimulation syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles.MedGenMed. 2005 Aug 16;7(3):60. MedGenMed. 2005. PMID: 16369286 Free PMC article.
-
Use of buserelin and low-dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome.J Assist Reprod Genet. 1995 Apr;12(4):252-7. doi: 10.1007/BF02212927. J Assist Reprod Genet. 1995. PMID: 7580021 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources